`
`JJJJJJJJJJJJJJJJ
`
`478AD7 F97 B3F7@F FD;3> 3@6 3BB73> 4A3D6
`
`JJJJJJJJJJJJJJJJ
`
`4AEFA@ E5;7@F;8;5 5ADBAD3F;A@ KXN
`4AEFA@ E5;7@F;8;5 E5;?76$ ;@5&
`BO]S]SYXO[
`
`_&
`
`H3E5G>3D EA>GF;A@E$ ;@5&
`BK]OX] A‘XO[
`
`JJJJJJJJJJJJJJJJ
`
`5K\O ;BD2 GXK\\SQXON
`BK]OX] 0$(,0$(+*
`
`JJJJJJJJJJJJJJJJ
`
`3]]Y[XOb 6YMUO] @Y& ((*-*).%(((-/
`
`JJJJJJJJJJJJJJJJ
`
`(’-#) ’$ !++’)&#.
`
`
`
`Pursuant to 37 C.F.R. § 4210(1)), Petitioner, Boston Scientific Corporation and Boston
`
`Scientific Scimed, 1110., hereby appoint David R. Marsh (Reg. No. 41,408) as lead counsel,
`
`Kristan L. Lansbery (Reg. No. 53,183) as back-up counsel, and all of Arnold & Porter LLP, to
`
`represent the Petitioner before the Patent Trial and Appeal Board in the United States Patent and
`
`Trademark Office, and to transact all business associated with the inter partes reviews of U.S.
`
`Patent Nos. 8,142,413, 8,048,032, and 8,292,850.
`
`Respectfully Submitted,
`
`Wm)? %[5
`
`j
`
`Peter J. Gafner
`
`"
`
`Vice President Cardiovascular Litigation
`Boston Scientific Corporation
`
`Date: May 14, 2014
`
`
`
`
`
`"#)+%$%"!+# ’$ *#),%"#
`
`FRO ^XNO[\SQXON MO[]SPSO\ ]RK] K MYZb YP ]RO BO]S]SYXO[c\ BY‘O[ YP
`
`3]]Y[XOb ‘K\ \O[_ON Lb NOZY\S]SXQ ]RO \KWO ‘S]R C^SMU ;X]O[XK]SYXKV 5Y^[SO[ YX
`
`16
`?Kb )-$ *(),$ ]Y ]RO GEBFA MY[[O\ZYXNOXMO KNN[O\\ YP [OMY[N VS\]ON LOVY‘2
`
`BK]]O[\YX$ FR^OX]O$ BO]O[\OX$ B3
`,0(( ;6E 5OX]O[
`0( EY^]R 0]R E][OO]
`?SXXOKZYVS\$ ?@ --,(*%*)((
`
`5Y^[]O\b MYZSO\ ‘O[O KV\Y \RSZZON ]Y MY^X\OV PY[ ZK]OX] Y‘XO[ K] ]RO
`
`PYVVY‘SXQ KNN[O\\2
`
`<& FRYWK\ HS]]
`9OK]RO[ DONWYXN
`ERKXXYX 4TY[UV^XN
`8Y[[O\] FKRNYYKRXSZZKR
`6Y[\Ob ! IRS]XOb
`-( EY^]R ESa]R E][OO]
`E^S]O )-((
`?SXXOKZYVS\$ ?@ --,(*
`FOVOZRYXO2 ".)*# +,(%*.((
`
`’6K_SN D& ?K[\R’
`6K_SN D& ?K[\R "3]]b& DOQ& @Y& ,)$,(0#
`3D@A>6 ! BADF7D >>B
`--- )*]R E][OO]$ @&I&
`IK\RSXQ]YX$ 6&5& *(((,
`FOV2 "*(*# 1,*%-(.0
`8Ka2 "*(*# 1,*%-111
`
`